ClinicalTrials.gg
RecruitingNCT06180590Updated Mar 13, 2024

The Efficacy of Vosevi in Treating DAA-experienced Patients

An observational study in Chronic Hepatitis C and Medication Reaction, sponsored by The Third Affiliated Hospital of Guangzhou Medical University. Recruiting at 1 site in China. Open to participants aged 20 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-03-13.

Sponsored by The Third Affiliated Hospital of Guangzhou Medical University · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Feb 2026, 8 months ago, but the record still lists the study as recruiting.
  • Started Feb 2023; still recruiting 3 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
200
Ages
20 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 44 studies in Hepatitis C, Chronic with a site in China — 2 open to participants now, 2 under way, none of them phase 3. Hepatitis C, Chronic · China.

Planned enrollment
8th of 10
200 · median 300
Started
2023
with 1 other
Observational
10 of 44
2 open now
Registered
44th of 44
by date

Among the 44 studies in Hepatitis C, Chronic with a site in China, this one is the 8th largest by planned enrollment of the 10 observational ones that give a count, is one of 2 that started in 2023, is one of 10 observational ones, and was the 44th registered.

Hepatitis C, Chronic

950 studies on the registry are indexed under Hepatitis C, Chronic; 8 are open to participants now.

Browse Hepatitis C, Chronic studies →

Open to participants now

2 of the 44 studies in Hepatitis C, Chronic with a site in China are open now. Recruiting first, the newest first:

All 2 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 5 Hepatitis C, Chronic studies recruiting now, 2 set no upper age limit and 2 stop at 75 or younger; 1 takes children under 18; 1 takes healthy volunteers.

This study: 20 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies in Hepatitis C, Chronic with a site in China, or all of them as a file.
02

Study summary

Hepatitis C virus (HCV) infection remains a significant health problem in our country. The World Health Organization estimated that 71 million people worldwide had chronic HCV infection in 2015. And 399,000 people died from cirrhosis or primary hepatocellular carcinoma caused by HCV infection. In 2006, the positive rate of HCV antibody in the population aged 1-59 was 0.43%. Therefore, it was estimated that there were about 5.6 million HCV infected people in the general population, and about 10 million cases of HCV infected people in high-risk groups and high incidence areas.

Universal genotype direct antiviral agent (DAA) is the preferred antiviral therapy for hepatitis C. Sofosbuvir/velpatasvir are direct antiviral agents for hepatitis C. The results of Asian clinical trials mainly in Chinese population showed that the sustained virologic response (SVR) rates of sofosbuvir/velpatasvir at 12 weeks in genotype 1a, 1b, 2, 3a, 3b and 6 were 100%, 100%, 100%, 95%, 76% and 99%, respectively. Limited data showed that the SVR rate of sofosbuvir/velpatasvir at 12 weeks was 96% in Chinese genotype 3b patients without cirrhosis and 50% in patients with cirrhosis.

After standard antiviral therapy for hepatitis C, there are still some patients who cannot obtain SVR, and these patients are defined as DAA-experienced patients. The guidelines recommend that Sofosbuvir/Velpatasvir combined with ribavirin be used as salvage therapy for patients with DAA-experienced failure. Vosevi is a new generation of antiviral therapy for hepatitis C, which contains three components, (Sofosbuvir, Velpatasvir and Voxilaprevir. It was a salvage treatment plan for DAAs-experienced patients which was recommended by the Chinese hepatitis C prevention and treatment guidelines in 2019. However, there are insufficient data on the proportion of SVR acquired in Vosevi treated DAAs-experienced patients in Asian populations and the effectivity of antiviral therapy between Vosevi and Sofosbuvir/Velpatasvir combined with ribavirin.

In the present study, the investigators enroll DAAs-experienced hepatitis C patients. The participants are randomly divided into two groups. Then the participants are treated with Vosevi or Sofosbuvir/Velpatasvir combined with ribavirin respectively. All enrolled participants are followed-up for 3 years. Objectives of the present study are as follows:

A. To clarify the sustained virologic response rate after Vosevi therapy for DAAs-experienced patients.

B. To clarify the safety and efficacy between the Vosevi therapy and the Sofosbuvir/Velpatasvir combined with ribavirin therapy.

C. To clarify the changes of biochemistry indexes in DAAs-experienced patients after Vosevi therapy.

D. To clarify the virological relapse rate at 12 weeks after Vosevi therapy. E. To clarify the rate of cirrhosis and liver cancer during the follow-up.

03

Conditions studied

  • Chronic Hepatitis C
  • Medication Reaction

Keywords

  • Vosevi
  • Efficacy
  • DAAs-experienced
  • Sustained Viral Response
04

Who can participate

Ages eligible
20 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

We enroll DAAs-experienced hepatitis C patients in The Third Affiliated Hospital of Guangzhou Medical University

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age of 20-70 years.
  • Accepted the standard direct antiviral agent before
  • still positive
  • Patients are administrated with once-daily oral Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir: 400mg/100mg/100mg) or Sofosbuvir/Velpatasvir (400mg/100mg) combined with ribavirin(500mg)twice a day treatment for rescue therapy.
  • The good compliance of patients.

Exclusion criteria

Exclusion Criteria:

  • Patients with antibodies against , , HDV, concretion or other forms of infectious disease.
  • Evidence of hepatocellular carcinoma, decompensated liver disease, auto-immune hepatitis, or significant renal, cardiovascular, respiratory or neurological comorbidity.
  • Concurrent treatment with , cytotoxic drugs, nonsteroidal anti-inflammatory drugs, or immune modulators.
  • Pregnancy.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
200 participants (estimated)
Patient registry
No

Groups and cohorts

  • Vosevi Group

    Patients are administrated with once-daily oral Vosevi (Sofosbuvir/Velpatasvir/Voxilaprevir: 400mg/100mg/100mg)

    Drug: Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi]

  • Sofosbuvir/Velpatasvir combined with ribavirin Group

    Patients are administrated with once-daily oral Sofosbuvir/Velpatasvir (400mg/100mg) combined with ribavirin(500mg)twice a day

    Drug: Sofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi]

Interventions

  • DrugSofosbuvir / Velpatasvir / Voxilaprevir Oral Tablet [Vosevi]

    Evaluate the efficacy of Vosevi in DAAs-experienced patients

06

What researchers measure

Primary outcomes

  1. The proportion of sustained virologic response after antiviral therapy

    Testing HCV-RNA in patients after antiviral therapy using Vosevi or Sofosbuvir/Velpatasvir combined with ribavirin

    Time frame: in one week after completed the antiviral therapy

Secondary outcomes

  1. The proportion of ALT normalization after antiviral therapy

    Testing for ALT level in patients after antiviral therapy using Vosevi or Sofosbuvir/Velpatasvir combined with ribavirin

    Time frame: in one week after completed the antiviral therapy

  2. The proportion of virologic relapse after antiviral therapy

    Testing HCV-RNA in patients at 12 weeks during off-treatment

    Time frame: in 12 weeks after completed the antiviral therapy

  3. The proportion of hepatitis C patients developed into cirrhosis or liver cancer during off-treatment

    Testing in patients every half a year during off-treatment

    Time frame: Liver ultrasound every half a year after completed the antiviral therapy until the study ending

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Feb 2026, 36 months after the start.

Of 38 non-industry observational studies under Hepatitis C, Chronic, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 110. This study's planned 36 months is below that.

Counting every sponsor, half of 72 studies reached it within 32 months; a quarter within 22 and three quarters within 54.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2023
First posted
Dec 22, 2023
StartActual
Feb 28, 2023
Primary completionEst.
Feb 28, 2026
CompletionEst.
Feb 28, 2027
Last update
Mar 13, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06180590
Lead sponsor
The Third Affiliated Hospital of Guangzhou Medical University
Responsible party
Sponsor
First posted
Dec 22, 2023
Start date
Feb 28, 2023
Primary completion
Feb 28, 2026 (estimated)
Completion
Feb 28, 2027 (estimated)
Last update
Mar 13, 2024

Study contacts

Xingfei Pan, PhD
Contact
panxf0125@163.com
13662517686
Xingfei Pan, PhD
study director · The Third Affiliated Hospital of Guangzhou Medical University

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion